Browsing by Author "Pereira, Dario Elias"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment.
    (2021) Mazzeti, Ana Lia; Gonçalves, Karolina Ribeiro; Mota, Suianne Letícia Antunes; Pereira, Dario Elias; Diniz, Lívia de Figueiredo; Bahia, Maria Terezinha
    Drug combinations have been evaluated for Chagas disease in an attempt to improve efficacy and safety. In this line, the objective of this work is to assess the effects of treatment with nitro drugs combinations using benznidazole (BZ) or nifurtimox (NFX) plus the sulfone metabolite of fexinidazole (fex-SFN) in vitro and in vivo on Trypanosoma cruzi infection. The in vitro interaction of fex-SFN and BZ or NFX against infected H9c2 cells by the Y strain was classi- fied as an additive (0.5⩾ΣFIC<4), suggesting the possibility of a dose reduction in the in vivo T. cruzi infection. Next, the effect of combining suboptimal doses was assessed in an acute model of murine T. cruzi infection. Drug combinations led to a faster suppression of parasit- emia than monotherapies. Also, the associations led to higher cure levels than those in the reference treatment BZ 100 mg day−1 (57.1%) (i.e. 83.3% with BZ/fex-SFN and 75% with NFX/fex-SFN). Importantly, toxic effects resulting from the associations were not observed, according to weight gain and hepatic enzyme levels in the serum of experimental animals. Taken together, this study is a starting point to explore the potential effects of nitro drugs combinations in preclinical models of kinetoplastid-related infections.
  • No Thumbnail Available
    Item
    Vasoactive intestinal peptide reduces the inflammatory profile in mice infected with Trypanosoma cruzi.
    (2015) Higyno, Pulchéria Maria Silva; Mendes, Priscila Fagundes; Miranda, Marina Barcelos de; Pereira, Dario Elias; Mota, Ana Paula Lucas; Nogueira, Katiane de Oliveira Pinto Coelho; Caldas, Ivo Santana; Moura, Sandra Aparecida Lima de; Menezes, Cristiane Alves da Silva
    Vasoactive intestinal peptide (VIP) has gained great prominence because of its therapeutic potential, which is ascribed to its ability to regulate innate immunity, inhibit antigen-specific Th1 cell responses, and generate T regulatory cells. Additionally, VIP may act as a natural antimicrobial peptide, killing bacteria, fungi, and infective forms of Trypanosoma brucei. Despite the possible relevance of VIP during the course of Chagas disease, studies regarding this in human and experimental Trypanosoma cruzi infections remain poorly characterized. In this work, we evaluated the effects of VIP on systemic and cardiac immune responses during experimental acute infection. C57BL/6 mice were infected with 5000 trypomastigotes of the VL-10 strain of T. cruzi and treated with intraperitoneal VIP injection every other day for one month. After 30 days, we observed no reduction in parasitemia levels. However, we observed a reduction in serum levels of IFN-gamma and IL-2 and an increase in that of IL-4. These data suggest that VIP treatment modified immune responses to favor the Th2 response, which had no impact on parasitemia levels although the serum level of IFN-gamma was reduced. However, this change in immune balance reduced heart damage, as noted by the smaller cardiac volume and the moderate inflammatory.